Complications of using Methylphenidate as therapy In pediatric ADHD
DOI:
https://doi.org/10.36557/2674-8169.2024v6n12p1573-1600Keywords:
Transtorno de Déficit de Atenção e Hiperatividade, Metilfenidato, Efeitos adversos, PediatriaAbstract
Introduction: Attention deficit hyperactivity disorder (ADHD) is a common diagnosis in pediatrics, primarily characterized by attention difficulties, hyperactivity, and impulsivity. The aim of this study was to discuss complications associated with the use of Methylphenidate as a treatment for ADHD in pediatric patients, in order to mitigate adverse effects and achieve optimal therapeutic outcomes. Methodology: This was an integrative literature review. The Health Sciences Descriptors (DeCS/MeSH) platform was utilized with the keywords "ADHD" AND "Methylphenidate" AND "Complications" AND "Children" in both English and Portuguese. A search was conducted in PubMed, BVS, and Scopus databases, yielding 140 studies. Inclusion criteria were articles that were "free full text", published within the last 5 years, relevant to the research question, and in either Portuguese or English. Ultimately, 37 articles were included, with 11 duplicates removed, leaving 26 for this study. Results: Adverse effects associated with Methylphenidate use in pediatric patients diagnosed with Attention Deficit Hyperactivity Disorder were observed, such as reduced sleep time, growth restriction, visual impairments, and agitation. Conclusion: Therefore, it was evident that there are various repercussions linked to Methylphenidate use in pediatric patients with ADHD. Given these multifactorial effects, understanding each patient's condition is crucial to finding the best therapeutic approach and mitigating unfavorable outcomes associated with Methylphenidate use.
Downloads
References
Ornoy A, Koren G. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 2021;19(11):1794-1804. doi: 10.2174/1570159X18666201127164000. PMID: 33245274; PMCID: PMC9185785.
Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics. 2020 Oct;51(5):315-335. doi: 10.1055/s-0040-1701658. Epub 2020 Jun 19. PMID: 32559806; PMCID: PMC7508636.
Leffa DT, Caye A, Rohde LA. ADHD in Children and Adults: Diagnosis and Prognosis. Curr Top Behav Neurosci. 2022;57:1-18. doi: 10.1007/7854_2022_329. PMID: 35397064.
Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. PMID: 34174276.
GANONG, L. H. Integrative reviews of nursing research. Research in Nursing & Health, v. 10, n. 1, p. 1–11, fev. 1987
SOUZA, Marcela Tavares de; SILVA, Michelly Dias da ; CARVALHO, Rachel de. Integrative Review: What Is It? How to Do It? Einstein (São Paulo), v. 8, n. 1, p. 102–106, 2010. Disponível em: <https://doi.org/10.1590/s1679-45082010rw1134>.
TSUJII, N. et al. Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review. Neurology and Therapy, v. 10, n. 2, p. 499–522, 4 jun. 2021.
ROSENAU, P. T. et al. Withdrawing methylphenidate in relation to serum levels of ferritin and zinc in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Psychiatric Research, v. 152, p. 31–37, 1 ago. 2022.
LILJA, M. M. et al. The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort. Journal of Neurodevelopmental Disorders, v. 14, n. 1, p. 17, 6 mar. 2022.
KARAHMADI, M.; SAADATMAND, S.; TARAHI, M. J. Investigation of Efficacy of Short-Acting Methylphenidate (Ritalin) and Long-Acting (Matoride) on Symptoms of Attention Deficit Hyperactivity Disorder in Children Aged 6–18 Years: A Single-Blind, Randomized Clinical Trial. Advanced Biomedical Research, v. 9, n. 1, 29 maio 2020.
EATON, C. et al. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy. Cochrane Database of Systematic Reviews, v. 2022, n. 7, 13 jul. 2022.
AYDEMIR, E.; AYDEMIR, G. A.; KALINLI, M. Evaluation of ocular surface in children with attention deficit hyperactivity disorder with respect to methylphenidate treatment. Arquivos Brasileiros de Oftalmologia, 23 set. 2022.
MOHAMMADZADEH, S. et al. Effect of omega-3 plus methylphenidate as an alternative therapy to reduce attention deficit-hyperactivity disorder in children. Korean Journal of Pediatrics, v. 62, n. 9, p. 360–366, 1 set. 2019.
PAI, L.-F. et al. New insights into precocious puberty and ADHD: a nationwide cohort study. Pediatr Res, p. 1787–1794, dez. 2022.
CHEN, V. C.-H. et al. Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study. Eur Child Adolesc Psychiatry, p. 361–368, fev. 2022.
KUROKAWA, S. et al. Gastrointestinal symptoms and sensory abnormalities associated with behavioral problems in children with neurodevelopmental disorders. Autism Res, p. 1996–2001, set. 2021.
ROCHE, M. et al. Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome. J Intellect Disabil Res, p. 795–800, 2021.
JOSHI, G.; WILENS, T. E. Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am, p. 449–468, 2022.
LEEMAN-MARKOWSKI, B. A. et al. Methylphenidate for attention problems in epilepsy patients: Safety and efficacy. Epilepsy Behav, p. 107627–107627, 2021.
MILLER, J.; PERERA, B.; SHANKAR, R. Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Expert Opin Pharmacother, p. 1897–1913, 2020.
DEFRODA, S. F. et al. The effects of methylphenidate on stress fractures in patients’ ages 10-29: a national database study. Phys Sportsmed, p. 412–416, 2020.
KAALUND-BROK, K. et al. Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD. PLOS ONE, v. 16, n. 10, p. e0253727, 21 out. 2021.
OUADIH-MORAN, M. et al. Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and ω-3 PUFAs. Nutrients, v. 15, n. 3, p. 712–712, 31 jan. 2023.
MAEDER, J. et al. Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial. The International Journal of Neuropsychopharmacology, v. 25, n. 3, p. 215–225, 17 mar. 2022.
AKKAYA, S. et al. Assessment of the lamina cribrosa in attention-deficit hyperactivity disorder. Indian Journal of Ophthalmology, v. 69, n. 12, p. 3607, 1 dez. 2021.
BINGÖL-KIZILTUNÇ, P.; YÜRÜMEZ, E.; ATILLA, H. Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder? - A prospective, one year follow-up study. Indian Journal of Ophthalmology, v. 70, n. 5, p. 1664–1668, 1 maio 2022.
SASAKI, Y. et al. Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan. PLOS ONE, v. 16, n. 6, p. e0252420, 3 jun. 2021.
TSO, W. et al. Early sleep deprivation and attention-deficit/hyperactivity disorder. Pediatric Research, v. 85, n. 4, p. 449–455, 1 mar. 2019.
ARAIN, F. et al. Stimulant induced Dermatological and Vascular Complications in patients with ADHD: A literature review. European Psychiatry, v. 65, n. S1, p. S420–S420, 1 jun. 2022.
BRIKELL, I. et al. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. American Journal of Psychiatry, v. 178, n. 9, p. appi.ajp.2020.2, 22 jun. 2021.
SANABRA, M. et al. Deficient Emotional Self-Regulation and Sleep Problems in ADHD with and without Pharmacological Treatment. Journal of Attention Disorders, p. 108705472098624, 20 jan. 2021.
ROSS, L. et al. Dose Adjustment of Stimulants for Children with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review of the Impact of Exceeding Recommended Doses. CNS Drugs, v. 34, n. 6, p. 643–649, 16 abr. 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Amanda Safira Araújo Mendes, Anne Caroline D’avila Pinheiro Daniel, Marianna Carla Santos Maciel, Rodrigo Dantas do Nascimento Filho, Luanny Rabelo Dantas Maia Patrício de Figueiredo, Vinicius Augusto Santos Varela Barca Bacurau, Maria Oitava Rosado Cantídio, Ana Larissa Fernandes De Holanda Soares
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
